Back to discover
Disease

Hepatomegaly

Late-stage therapeutic developmentEmerging research
MeSHHepatomegaly
1
Publications
7
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q4 2028.
Upcoming Milestones
Major developments
Upcoming trial readoutImportant
Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
Results expected Q4 20282025-12-23
Major trial resultsImportant
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
Results posted2025-09-09
Clinical Milestones2View
Results posted 1
Results expected 1
Activity timeline2

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Imigluceraseapproved

Approval — Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in pa… (1997)

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
7
All trials
2
Active
2
Late-stage
3
Completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
1997emaApproval — Imiglucerase· Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: anaemia after exclusion of other causes, such as iron deficiency Thrombocytopenia Bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Annals of hepatology · 2024 · 472 cites
Recent publications

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Annals of hepatology · 2024 · 472 cites
Major themes1
  • Non-alcoholic Fatty Liver Disease1
Leading journals1
  • Annals of hepatology1
Leading researchers8
  • Abdelmalek MF1
  • Anstee QM1
  • Arab JP1
  • Arrese M1
  • Bataller R1
  • Beuers U1
  • Boursier J1
  • Bugianesi E1
Affiliations (unnormalised)6
  • Angers University Hospital1
  • Antwerp University Hospital1
  • Austral University Hospital1
  • Barcelona Institute for Global Health (ISGlobal)1
  • Baylor College of Medicine1
  • Centre for Liver Disease Research1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Enlargement of the liver.

Identifiers
MeSHHepatomegaly
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.